author-photo

Yu Kato

Eisai

15

Papers

257

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

Inhibition of FGFR reactivates IFNγ signaling in tumor cells to enhance the combined antitumor activity of lenvatinib with anti-PD-1 antibodies.

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
E7386, a selective inhibitor of the interaction between β-catenin and CBP, exerts antitumor activity in tumor models with activated canonical Wnt signaling.

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (4)
Abstract 1437: E7386, a CREB binding protein (CBP)/β-catenin interaction inhibitor, suppresses the hypoxic response induced by angiogenesis inhibition in hepatocellular carcinoma models

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Discovery of a Potent and Selective Axl Inhibitor in Preclinical Model

2021 Bioorganic & Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (2)
Biomarker results and preclinical rationale for combination lenvatinib and pembrolizumab in advanced endometrial carcinoma.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Abstract 5172: E7386, an orally active CBP/beta-catenin modulator, induces T cells infiltration into tumor and enhances antitumor activity of anti-PD-1 mAb in Wnt1 tumor syngeneic mice model

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Lenvatinib mesilate (LEN) enhanced antitumor activity of a PD-1 blockade agent by potentiating Th1 immune response

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (20)
Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway‐induced resistance to vascular endothelial growth factor receptor inhibitor

2014 Cancer Science
Show All
- Source
- Cite
- Save
Citations (19)